Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CDT vs VCIG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCIG Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 3–3 Matrix Metrics)

VCIG Overall Winner 6-Pillar Tally: CDT 2 – 3 VCIG (1 Tie) Matrix Metrics: CDT 3 – 3 VCIG

As of Nov 20, 2026, VCI Global Limited Ordinary Share (VCIG) is the stronger overall head-to-head candidate over CDT Equity Inc. (CDT) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). CDT carries a Unified Composite Score of 31.6/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin), whereas VCIG carries 35.1/100 (SELL) at $2.66 (N/M Forward P/E, -444.5% operating margin).

  • Growth vs. Quality Trade-Off: VCIG earns the overall head-to-head edge with a stronger Unified Composite Score (35.1/100 SELL vs. CDT 31.6/100 SELL) and -16.05β · 16019% Vol risk profile, whereas CDT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although VCIG compares more favorably head-to-head, both CDT (31.6/100 SELL) and VCIG (35.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: CDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1); meanwhile VCIG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CDT vs VCIG
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -17.75β · 10175% Vol
Unified Composite Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -58.9%), weak momentum, RSI 44
RSI-14: 44.1 · SMA20: $0.31 · SMA50: $0.40
VCIG NASDAQ Head-to-Head Winner
VCI Global Limited Ordinary Share
Services-Facilities Support Management Services
$2.66
-13.07% 1D
Market Cap $1.6M
TTM Revenue $9.9M
Forward P/E N/M
Beta / 30D Vol -16.05β · 16019% Vol
Unified Composite Score
35.1 / 100 SELL
Tech 15.0 Fund 33.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $3.63 · SMA50: $2.08

6-Pillar Scorecard Institutional Category Breakdown (CDT 2 – 3 VCIG)

Columns: Metric · CDT · VCIG
1. Valuation Multiples VCIG
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 0.2x
2. Growth & Scale CDT
Revenue Growth (YoY) +0.0% -86.4%
Earnings Growth (YoY) +0.0% -83.8%
TTM Revenue (USD) N/A $9.9M
Market Cap $507,528 $1.6M
3. Profitability & Quality CDT
Gross Margin N/A N/A
Operating Margin 0.0% -444.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -69.7% -31.1%
4. Balance Sheet & Cash Flow VCIG
Cash Generation (TTM) N/A -$43M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $435,000 Net Debt (0.01x D/E) $3335.46 Book/Sh · -31.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VCIG
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Consulting Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CDT (3) vs VCIG (3)
Institutional Metric CDT VCIG Criterion Row Edge
Market Capitalization
Scale
$507,528 $1.6M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -86.4% Higher Growth CDT
Operating Margin (TTM)
Profitability
0.0% -444.5% Higher Margin CDT
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-69.7% -31.1% Higher ROE VCIG
52-Week Range Position
Momentum
2% ($0–$11) 11% ($0–$23) Stronger Trend VCIG
Beta / 30D Volatility
Risk Regime
-17.75β · 10175% Vol -16.05β · 16019% Vol Lower Realized Risk CDT
Unified Institutional Score
Composite Signal
31.6 / 100 (SELL) 35.1 / 100 (SELL) Higher Composite VCIG
Trailing 12M Revenue (USD)
Operating Scale
N/A $9.9M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($435,000 Net Debt (0.01x D/E)) -$43M EBITDA ($3335.46 Book/Sh · -31.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VCIG +812.06 pp
CDT: +76.79% · VCIG: +888.85%
3M Horizon VCIG +80.32 pp
CDT: -90.76% · VCIG: -10.44%
6M Horizon VCIG +178.1 pp
CDT: -78.1% · VCIG: +100.0%
1Y Horizon VCIG +204.81 pp
CDT: -86.78% · VCIG: +118.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CDT vs VCIG. Trailing 12-month operating profitability (CDT 0.0% vs VCIG -444.5%) and valuation multiples (CDT N/M vs VCIG N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CDT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-69.7% · N/M
VCIG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$9.9M
Gross MarginN/A
Op. Margin-444.5%
ROE / Fwd P/E-31.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CDT BREAKDOWN
163d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VCIG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VCIG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CDT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $507,528 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VCIG Moat Profile Cyclical / Execution-Driven Positioning
Consulting Services Operator
Competes within the Consulting Services value chain with $1.6M market capitalization and -444.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CDT vs VCIG Key Questions & Quantitative Answers

As of Nov 20, 2026, VCI Global Limited Ordinary Share (VCIG) is the stronger overall head-to-head candidate over CDT Equity Inc. (CDT) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). CDT carries a Unified Composite Score of 31.6/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin), whereas VCIG carries 35.1/100 (SELL) at $2.66 (N/M Forward P/E, -444.5% operating margin). Growth vs. Quality Trade-Off: VCIG earns the overall head-to-head edge with a stronger Unified Composite Score (35.1/100 SELL vs. CDT 31.6/100 SELL) and -16.05β · 16019% Vol risk profile, whereas CDT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although VCIG compares more favorably head-to-head, both CDT (31.6/100 SELL) and VCIG (35.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: CDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1); meanwhile VCIG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDT leads the Growth & Scale pillar: CDT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VCIG at -86.4% YoY revenue growth and -83.8% YoY earnings growth on $9.9M TTM revenue (N/A gross margin, -444.5% operating margin). On trailing 12-month operating scale, CDT generates N/A in USD-normalized revenue versus $9.9M for VCIG. In operating R&D and SG&A reinvestment, CDT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VCIG.

VCIG screens cheaper on headline valuation multiples. CDT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas VCIG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.2x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDT (-69.7% ROE) versus VCIG (-31.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CDT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (-17.75β · 10175% Vol realized risk). By comparison, VCIG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-16.05β · 16019% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.